These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30963514)

  • 1. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis.
    Zhao H; Ning Y; Cooper J; Refoios Camejo R; Ni X; Yi B; Parks D
    Adv Ther; 2019 Jun; 36(6):1252-1265. PubMed ID: 30963514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
    Kulisevsky J; Pagonabarraga J
    Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis.
    Chen XT; Zhang Q; Chen FF; Wen SY; Zhou CQ
    Front Neurol; 2023; 14():1183823. PubMed ID: 37396766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of non-ergot dopamine-receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta-analysis.
    Chen XT; Zhang Q; Wen SY; Chen FF; Zhou CQ
    Eur J Neurol; 2023 Mar; 30(3):762-773. PubMed ID: 36380711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
    J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study.
    Chung SJ; Kim JM; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
    Expert Opin Pharmacother; 2015 May; 16(7):961-70. PubMed ID: 25846031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
    Etminan M; Gill S; Samii A
    Drug Saf; 2003; 26(6):439-44. PubMed ID: 12688834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis.
    Wang Y; Jiang DQ; Lu CS; Li MX; Jiang LL
    Medicine (Baltimore); 2021 Nov; 100(44):e27511. PubMed ID: 34871213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson's Disease: a Network Meta-Analysis.
    Li BD; Cui JJ; Song J; Qi C; Ma PF; Wang YR; Bai J
    Cell Physiol Biochem; 2018; 45(1):119-130. PubMed ID: 29339630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
    Gencler OS; Oztekin N; Oztekin MF
    Ideggyogy Sz; 2022 Jan; 75(1-02):39-49. PubMed ID: 35112520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
    Pahwa R; Stacy MA; Factor SA; Lyons KE; Stocchi F; Hersh BP; Elmer LW; Truong DD; Earl NL;
    Neurology; 2007 Apr; 68(14):1108-15. PubMed ID: 17404192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
    Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I;
    Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
    Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
    Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.